The Major Biotech Problem We All Can Help Solve

This article is brought to you by Equifund Technologies, LLC.

Share on facebook
Share on twitter
Share on linkedin

Ryan Cole
Start-ups in the biotech space have a unique issue with a common problem…


Specifically, how much runway (i.e. money) a biotech company will need before it can start producing sufficient cash flow to survive on its own.

It’s one of the main reasons biotech companies have been treated differently in the VC space for years.

But times are changing ­— and rapidly, thanks to new guidelines surrounding Reg-A+ and Reg-CF fundraising.

Back to that in a moment. First, let’s understand the unique problems facing biotech firms just starting…

Why Biotechs Need Funding More Than Other Sectors

When a tech whiz kid invents a shiny new piece of software, he can start selling it immediately.

Those sales create cash flow. And that cash flow creates runway — or, the amount of time a company can survive before hitting a crash point.

The invention of a new product is similar.

When a doodad factory starts churning out doodads, all the inventor needs is distribution — not an effortless lift, but far from a huge encumbrance.

But when a smart doctor or research scientist comes up with an idea for a new drug… or treatment… or medical tool…

Well, now you’re looking at a multi-years-long qualification process that if — and only if — you pass every test, could maybe lead to earning your first dollar sometime later this decade.

In a nutshell, this is why biotech companies have traditionally been beholden to VC funds and angel investors.

With no cash flow expected for years (or guarantee of any at all), biotech companies need huge sums of high-risk capital to continue their research, travel the regulatory pipeline, and hopefully survive to the point where sales start.

Naturally, VC Funds have taken advantage of this need for money. They’ve used it to squeeze founders out of companies and install their own boards.

Sometimes, VC’s go so far as to create their own companies and then bring in the “founders” — the folks with the vision — as hired help.

But no more…

Biotech Founders Are Finally Free

As you’ve heard many times in these pages, the rules surrounding the JOBS Act have changed recently.

Starting early next year, companies will be able to raise up to $5 million a year via crowdfunding — up from the million-plus limit that currently stands.

The higher amount could be plenty to keep a biotech firm afloat as it deals with the FDA and other governing bodies.

Which means biotech founders now have a choice…

  • Take VC money, with all the attached strings, and likely lose control of your company in the process?
  • Or have a crowdfunding round and get access to the capital you need, with fewer strings, and certainly no threats to founder authority.

What sounds like a better choice?

Granted — VC funds come with managerial and financial expertise that folks from other fields often lack.

But Y Combinator studies have shown companies run by business neophytes don’t suffer for it.

Instead, having the core vision represented at the top of the company more than makes up for any growing pains.

With that in mind, it’s little wonder that we’re expecting an avalanche of biotech deals in the crowdfunding space.

What This Change Means for Founders

To see what a difference this could make, here’s a case study…

Let’s look at a tiny biotech called Avectas. Based out of Ireland, Avectas specializes in mRNA treatment and delivery.

If mRNA is ringing a bell, that’s because the new COVID vaccines use mRNA techniques to get results.

It’s the first real application of mRNA tech — which, itself, is still so new we don’t know its full potential.

After all, if the coronavirus vaccines work… could mRNA treatments hold the key to defeating the common cold? The flu? HIV?

Avectas may very well be deeply involved in one of the most exciting medical breakthroughs of the age.

And if Avectas were to be initially formed next year, there’s a growing probability the company would use crowdfunding to raise seed capital.

Instead, founded in 2012, Avectas has gone to VC’s and angels to raise funds over the past two years. One investor — a scientist named Seamus Mulligan — is responsible for most of it, about $30 million.

Now, because Avectas is a private company, we don’t know the exact specifics of its financing rounds.

But it’s safe to assume the company gave up more equity and control early on, than it would have had it been founded next year under the new rules.

Indeed — Michael Macguire, founder and CEO of Avectas, is listed second-from-bottom on the Board of Directors.

Meanwhile, Mary Martin, an executive with previous connections to lead investor Seamus Mulligan, is the current Executive Chair of the Board of Directors.

The Ball Is Coming To Our Court

You can see why the Avectas’ of the future will seriously consider crowdfunding going forward.

If a biotech founder wants to retain control, but still raise money to buy a few years’ runway, it’s one of the best options available today — or will be, next year, when the funding limits are officially raised.

That’s why we’re expecting many biotech start-ups to enter this space in the coming months.

2021 will be the year biotech truly enters the crowdfunding arena.

Ryan Cole

Ryan Cole – Analyst

Like this article? Share it with a friend:

Share on facebook
Share on twitter
Share on linkedin

This article is not an Equifund Crowd Funding Portal Inc communication. It is brought to you by Equifund Technologies, LLC.

More Articles:

Don't make another private market investment without reading this...

The 5 Mistakes

investors make that crush returns

Download this free report now:

Just enter your name & email to access this report for free.

By submitting your email address you will receive access to this report and a free subscription to Equifund’s private investment newsletter. You can unsubscribe at any time and read more about our privacy policy here.

More Articles:


Kleiner Device Labs

Investment Highlights:

  • 1

    Proprietary devices that could revolutionize spinal surgery and greatly improve success rates, reduce pain, and lower costs.

  • 2

    Over 20 patents have been issued to protect the company's technologies.

  • 3

    Just received FDA clearance for their next-generation KG2 spinal fusion technology.

Pre-Investment Agreement

The next 8 slides will allow us to process your investment. Note that these next steps are a legal requirement – Thank you for your patience and financial support of this investment opportunity. Jordan Gillissie – CEO

Before we execute the investment, it’s important for us to make sure you’re comfortable and knowledgeable in early stage investing. We want to make sure that you:

    • Received and have reviewed the education materials sent to you.
    • UNDERSTAND; that there are restrictions on your ability to cancel your investment commitment and obtain a return of your investment.
    • KNOW; It may be difficult to resell securities acquired under Regulation Crowdfunding.
    • AGREE; investing in securities offered and sold in reliance on section 4(a)(6) of the Securities Act involves risk. Investors should not invest any funds unless he or she can afford to lose the entire amount of his or her investment. Your investment may not work out, and you must be in a financial condition to bear the loss.
  • Hidden
  • Hidden
  • Hidden
  • Hidden

We are currently upgrading our system. If you click submit and the process does not continue in a few seconds, please refresh this page manually, and click Invest Now again and you should be moved on to the next step.

Complete Your Registration

By verifying your account you agree with our terms of use, privacy policy and pre-dispute arbitration agreement. Please complete the registration process by clicking the link below:

Verify Your Email

Please wait a few minutes while we create your account. An email will be sent to you shortly to confirm your admittance. Should the email be delivered to your spam or promotions folder, we recommend you move it to your inbox and mark Equifund as a safe sender.

If you have not received the email in 5 minutes, please click here to have it resent.

Questions? Our customer service team is always here to help – 1-866-338-3004

Enter your email address to get instant access to the video: